Refine Search
(11)
(13)
(13)
(14)

Cardiovascular Diseases

The total revenue from branded cardiovascular drugs in 2017 is projected to be just over $40 billion. Top companies in this space are putting a heavy focus on the anti-thrombotic segment, as these drugs continue to bring in the biggest profit and dominate the cardiovascular market. Bayer currently holds the top spot in the market with 2017 sales of $5.4 billion; however, Sanofi and BMS come in a close second and third with sales of $5.1 and $4.7 billion, respectively.

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2018’, provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.

The report provides comprehensive information on the...

Atrial Fibrillation - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Atrial Fibrillation - Pipeline Review, H2 2018’, provides an overview of the Atrial Fibrillation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atrial...

Pulmonary Arterial Hypertension - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Pipeline Review, H2 2018’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics unde...

Pulmonary Embolism - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Pulmonary Embolism - Pipeline Review, H2 2018’, provides an overview of the Pulmonary Embolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonar...

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2018’, provides an overview of the Deep Vein Thrombosis (DVT) pipeline landscape.

The report provides comprehensive information on the therapeutics under developm...

Myocarditis - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Myocarditis - Pipeline Review, H2 2018’, provides an overview of the Myocarditis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocarditis, complete ...

Restenosis - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Restenosis - Pipeline Review, H2 2018’, provides an overview of the Restenosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Restenosis, complete wit...

Myocardial Infarction - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Myocardial Infarction - Pipeline Review, H2 2018’, provides an overview of the Myocardial Infarction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for My...

Arrhythmias - Pipeline Review, H2 2018

  • $2,000
  • August 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Arrhythmias - Pipeline Review, H2 2018’, provides an overview of the Arrhythmias pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete ...

Hypertension - Pipeline Review, H1 2018

  • $2,000
  • June 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Hypertension - Pipeline Review, H1 2018’, provides an overview of the Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertension, comple...

Myocardial Fibrosis - Pipeline Review, H1 2018

  • $2,000
  • June 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Myocardial Fibrosis - Pipeline Review, H1 2018’, provides an overview of the Myocardial Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocar...

Atherosclerosis - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Atherosclerosis - Pipeline Review, H1 2018’, provides an overview of the Atherosclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atherosclerosi...

Stroke - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Stroke - Pipeline Review, H1 2018’, provides an overview of the Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis b...

Septic Shock - Pipeline Review, H2 2016

  • $2,000
  • September 2016
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Septic Shock - Pipeline Review, H2 2016’, provides an overview of the Septic Shock pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Septic Shock, comple...